Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition containing meglumine cyclic adenosine monophosphate compound

A technology of meglumine cyclophosphate and a composition, applied in the field of medicine, can solve the problems of unsatisfactory dissolution speed, inconvenient use and the like, and achieve the effects of rapid dissolution, convenient use and good stability

Active Publication Date: 2014-04-16
姚云
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some products have unsatisfactory dissolution speed during clinical use, which causes inconvenient use. This invention provides a new prescription and preparation method, so that the medicine will not turn yellow when stored for a long time, and at the same time, the dissolution speed is improved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing meglumine cyclic adenosine monophosphate compound
  • Medicinal composition containing meglumine cyclic adenosine monophosphate compound
  • Medicinal composition containing meglumine cyclic adenosine monophosphate compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Cyclic adenosine meglumine 20g;

[0055] Mannitol 150g;

[0056] Calcium EDTA 2g;

[0057] Vitamin C 1.5g,

[0058] 2000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4;

[0059] Preparation

[0060] (1) Weigh the raw and auxiliary materials according to the prescription quantity

[0061] (2) Add mannitol, EDTA calcium, and vitamin C to 2000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4, and stir to dissolve.

[0062] (3) Add the prescribed amount of meglumine cyclic adenosine monophosphate into the solution and stir to dissolve completely. Stir to combine.

[0063] (4) Measure the pH value of the solution, which is 7.0.

[0064] (5) Fine filter with a 0.2 μm microporous membrane to check the clarity of the solution.

[0065] (6) According to the measurement results, fill the liquid medicine into a vial with a volume of about 2ml.

[0066] (7) Put the sample into a ...

Embodiment 2

[0069] Cyclic adenosine meglumine 20g;

[0070] Mannitol 100g;

[0071] Calcium EDTA 1g;

[0072] Vitamin C 1g,

[0073] 2000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4;

[0074] Preparation

[0075] Same as Example 1

Embodiment 3

[0077] Cyclic adenosine meglumine 20g;

[0078] Mannitol 200g;

[0079] Calcium EDTA 3g;

[0080] Vitamin C 2g,

[0081] 2000ml of disodium hydrogen citrate and trisodium citrate buffer solution with a molar ratio of 1:4;

[0082] Preparation

[0083] With embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicinal composition containing a meglumine cyclic adenosine monophosphate compound, and in particular relates to freeze-dried injection of meglumine cyclic adenosine monophosphate and a preparation method thereof. Each 1,000 injections are prepared from the following components: 20g of meglumine cyclic adenosine monophosphate, 100 to 200g of mannitol, 1 to 3g of ethylene diamine tetraacetic acid (EDTA) calcium, 1 to 2g of vitamin C, and 2,000ml of a buffer solution of disodium hydrogen citrate and trisodium citrate at a mole ratio of 1: 4.

Description

technical field [0001] The invention relates to a freeze-dried powder preparation of meglumine cyclic adenosine monophosphate and a preparation method thereof, belonging to the field of medicine. Background technique [0002] Cyclophosphate meglumine, English name: Meglumine Adenosine Cyclophosphate, is a salt of cyclic adenosine monophosphate and meglumine (1:1). Meglumine cyclic adenosine monophosphate is a non-digital cardiotonic agent, which has positive inotropic effect, can enhance myocardial contractility, improve myocardial pumping function, has the effect of dilating blood vessels, can reduce myocardial oxygen consumption; improve myocardial cell metabolism, protect Ischemic and hypoxic myocardium; can improve sinoatrial node P cell function. [0003] When meglumine cyclic adenosine monophosphate enters the human body, its half-life in the blood is 60-150 minutes. Because of its good hydrophilicity, especially its strong fat solubility, it is easier to enter the my...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/19A61K31/7076A61K47/26A61P9/00
Inventor 姚云
Owner 姚云
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com